JPMorgan raised the firm’s price target on Agios Pharmaceuticals to $31 from $30 and keeps a Neutral rating on the shares. The analyst updated the company’s model post the topline data from the phase 3 ENERGIZE trial evaluating mitapivat in patients with non-transfusion dependent thalassemia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AGIO:
- Agios Pharmaceuticals announces anticipated 2024 milestones
- Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
- Biotech Alert: Searches spiking for these stocks today
- Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
- Agios Pharmaceuticals: Phase 3 ENERGIZE study met primary endpoint